{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2,
    3,
    4,
    5,
    6,
    7,
    8,
    9,
    10,
    11,
    12,
    13,
    14,
    15,
    16,
    17,
    18,
    19,
    20,
    21,
    22,
    23,
    24,
    25,
    26,
    27,
    28,
    29,
    30,
    31,
    32,
    33,
    34,
    35,
    36,
    37,
    38,
    39,
    40,
    41,
    42,
    43,
    45,
    46,
    50,
    62,
    67,
    198,
    199,
    73,
    75,
    78,
    79
  ],
  "modelUsed": "gemini-3-flash-preview",
  "data": {
    "timeAnchors": [
      {
        "id": "anchor_1",
        "definition": "First administration of investigational product",
        "anchorType": "FirstDose",
        "timelineId": null,
        "dayValue": 1,
        "sourceText": "Day 1 dosing"
      },
      {
        "id": "anchor_2",
        "definition": "Baseline visit/assessment",
        "anchorType": "Baseline",
        "timelineId": null,
        "dayValue": 1,
        "sourceText": "baseline visit"
      },
      {
        "id": "anchor_3",
        "definition": "Screening visit",
        "anchorType": "Screening",
        "timelineId": null,
        "dayValue": 1,
        "sourceText": "Screening visit"
      },
      {
        "id": "anchor_4",
        "definition": "Informed consent obtained",
        "anchorType": "InformedConsent",
        "timelineId": null,
        "dayValue": 1,
        "sourceText": "Informed consent"
      },
      {
        "id": "anchor_5",
        "definition": "surgery",
        "anchorType": "Custom",
        "timelineId": null,
        "dayValue": 1,
        "sourceText": "surgery"
      }
    ],
    "repetitions": [
      {
        "id": "rep_daily_1",
        "type": "Daily",
        "interval": "P1D",
        "sourceText": "od"
      },
      {
        "id": "rep_daily_10",
        "type": "Daily",
        "interval": "P1D",
        "sourceText": "OD"
      },
      {
        "id": "rep_interval_1",
        "type": "Interval",
        "sourceText": "PK sampling at "
      },
      {
        "id": "rep_window_1",
        "type": "Continuous",
        "sourceText": "washout period"
      },
      {
        "id": "rep_window_3",
        "type": "Continuous",
        "sourceText": "Screening Period"
      },
      {
        "id": "rep_window_10",
        "type": "Continuous",
        "sourceText": "treatment period"
      },
      {
        "id": "rep_window_16",
        "type": "Continuous",
        "sourceText": "1 day after"
      },
      {
        "id": "rep_window_17",
        "type": "Continuous",
        "sourceText": "14 days post"
      },
      {
        "id": "rep_llm_1",
        "type": "Continuous",
        "startOffset": "P0D",
        "endOffset": "P0D",
        "interval": "P1D",
        "minObservations": 1,
        "exitCondition": "End of study",
        "sourceText": "Time period and frequency for collecting AE and SAE information"
      },
      {
        "id": "rep_llm_2",
        "type": "Cycle",
        "startOffset": "P0D",
        "endOffset": "P6D",
        "interval": "P1D",
        "minObservations": 6,
        "exitCondition": "Completion of 6 exposure days",
        "sourceText": "Participants should have at least 6 EDs to BIVV001 to be eligible for major surgery."
      },
      {
        "id": "rep_llm_3",
        "type": "Continuous",
        "startOffset": "-P7D",
        "endOffset": "P0D",
        "interval": "P7D",
        "minObservations": 1,
        "exitCondition": "null",
        "sourceText": "the PROMIS-SF Physical Function - SF 6b instrument does not use a 7-day recall period"
      },
      {
        "id": "rep_llm_4",
        "type": "Continuous",
        "startOffset": "-P28D",
        "endOffset": "P0D",
        "interval": "P28D",
        "minObservations": 1,
        "exitCondition": "null",
        "sourceText": "negative inhibitor test within 4 weeks prior to surgery"
      }
    ],
    "samplingConstraints": [],
    "traversalConstraints": [
      {
        "id": "traversal_crossover_1",
        "requiredSequence": [
          "SCREENING",
          "PERIOD_1",
          "WASHOUT",
          "PERIOD_2",
          "END_OF_STUDY"
        ],
        "allowEarlyExit": true,
        "exitEpochIds": [
          "EARLY_TERMINATION"
        ],
        "mandatoryVisits": [
          "Screening",
          "Day 1",
          "End of Study"
        ],
        "sourceText": "washout period"
      },
      {
        "id": "traversal_1",
        "requiredSequence": [
          "SCREENING",
          "BASELINE",
          "TREATMENT_PERIOD",
          "END_OF_STUDY"
        ],
        "allowEarlyExit": true,
        "exitEpochIds": [
          "EARLY_TERMINATION"
        ],
        "mandatoryVisits": [
          "End of Study",
          "Screening",
          "Day 1",
          "Baseline"
        ],
        "sourceText": "[{'condition': 'If subject requires major surgery', 'path': ['SURGERY_SUBGROUP', '6_EXPOSURE_DAYS_MINIMUM', 'NEGATIVE_INHIBITOR_TEST']}, {'condition': 'Use of FVIII products other than BIVV001 (non-emergency)', 'path': ['DEFINITIVE_DISCONTINUATION']}, {'condition': 'Life-threatening emergency requiring other FVIII product', 'path': ['SPONSOR_REVIEW', 'CONTINUATION_DECISION']}]"
      }
    ],
    "executionTypes": [
      {
        "activityId": "Blood Sample",
        "executionType": "Single",
        "rationale": "EPISODE signals: 2; SINGLE signals: 8"
      },
      {
        "activityId": "Vital Signs",
        "executionType": "Single",
        "rationale": "No strong signals detected"
      },
      {
        "activityId": "Pe",
        "executionType": "Single",
        "rationale": "No strong signals detected"
      },
      {
        "activityId": "Ae",
        "executionType": "Single",
        "rationale": "SINGLE signals: 6"
      },
      {
        "activityId": "Concomitant Medications",
        "executionType": "Single",
        "rationale": "SINGLE signals: 11; RECURRING signals: 3"
      },
      {
        "activityId": "Laboratory Assessments",
        "executionType": "Single",
        "rationale": "SINGLE signals: 1"
      },
      {
        "activityId": "Pharmacokinetic",
        "executionType": "Single",
        "rationale": "No strong signals detected"
      },
      {
        "activityId": "Pharmacodynamic",
        "executionType": "Single",
        "rationale": "No strong signals detected"
      },
      {
        "activityId": "Dosing",
        "executionType": "Single",
        "rationale": "WINDOW signals: 2; SINGLE signals: 8"
      },
      {
        "activityId": "Imaging",
        "executionType": "Single",
        "rationale": "SINGLE signals: 2"
      },
      {
        "activityId": "Questionnaire",
        "executionType": "Single",
        "rationale": "No strong signals detected"
      },
      {
        "activityId": "Haem-A-QoL (≥17 years old) Physical Health score",
        "executionType": "Single",
        "rationale": "Secondary efficacy endpoint measures like PROs are typically scheduled repeats at specific study visits as indicated in the SoA."
      },
      {
        "activityId": "PROMIS Pain Intensity 3a",
        "executionType": "Single",
        "rationale": "Patient-reported outcome measure collected at scheduled intervals to assess efficacy over the treatment period."
      },
      {
        "activityId": "Hemophilia Joint Health Score (HJHS)",
        "executionType": "Single",
        "rationale": "Total score measure used for secondary efficacy analysis, collected at scheduled study visits."
      },
      {
        "activityId": "Treatment Satisfaction Questionnaire for Medication (TSQM-9)",
        "executionType": "Single",
        "rationale": "Standardized questionnaire administered at multiple points to evaluate treatment satisfaction throughout the study."
      },
      {
        "activityId": "Exit Interview",
        "executionType": "Single",
        "rationale": "Conducted once at the end of the study for selected participants to evaluate expectations and perceptions of treatment impact."
      },
      {
        "activityId": "ABR (Annualized Bleed Rate) Monitoring",
        "executionType": "Single",
        "rationale": "Continuous collection of bleeding events over a 6-month study duration to calculate the annualized rate."
      }
    ],
    "crossoverDesign": {
      "id": "crossover_1",
      "isCrossover": true,
      "numPeriods": 2,
      "numSequences": 2,
      "periods": [
        "Period 1",
        "Period 2"
      ],
      "sequences": [
        "AB",
        "BA"
      ],
      "washoutDuration": "P96D",
      "washoutRequired": true,
      "sourceText": "washout period"
    },
    "footnoteConditions": [
      {
        "id": "fn_cond_1",
        "conditionType": "general",
        "text": "a. Screening may be accomplished over the course of more than 1 study visit if needed.",
        "footnoteId": "fn_1",
        "structuredCondition": "screening.visit_count >= 1",
        "appliesToActivityIds": [
          "Screening"
        ],
        "sourceText": "a. Screening may be accomplished over the course of more than 1 study visit if needed."
      },
      {
        "id": "fn_cond_2",
        "conditionType": "timing_before",
        "text": "b. Washout prior to BIVV001 Day 1 dose administration is at least 96 hours (4 days) if the participant is receiving a conventional FVIII product.",
        "footnoteId": "fn_2",
        "structuredCondition": "washout.duration >= P4D if product == 'conventional FVIII'",
        "appliesToActivityIds": [
          "BIVV001 Day 1 dose administration"
        ],
        "timingConstraint": "PT96H",
        "sourceText": "b. Washout prior to BIVV001 Day 1 dose administration is at least 96 hours (4 days) if the participa"
      },
      {
        "id": "fn_cond_3",
        "conditionType": "timing_after",
        "text": "c. Participants should schedule their study visits to be 7 ±1 day after the previous prophylactic dose of BIVV001.",
        "footnoteId": "fn_3",
        "structuredCondition": "visit.schedule == previous_dose + P7D +/- P1D",
        "appliesToActivityIds": [
          "Study visits"
        ],
        "sourceText": "c. Participants should schedule their study visits to be 7 ±1 day after the previous prophylactic do"
      },
      {
        "id": "fn_cond_4",
        "conditionType": "general",
        "text": "d. At this visit, participants in Arm B (on-demand treatment) switch to prophylaxis.",
        "footnoteId": "fn_4",
        "structuredCondition": "treatment_regimen.switch('prophylaxis') if arm == 'Arm B'",
        "appliesToActivityIds": [
          "Arm B treatment"
        ],
        "sourceText": "d. At this visit, participants in Arm B (on-demand treatment) switch to prophylaxis."
      },
      {
        "id": "fn_cond_5",
        "conditionType": "eligibility_conditional",
        "text": "e. Unscheduled visits may be necessary during the study to repeat any blood sampling if required.",
        "footnoteId": "fn_5",
        "structuredCondition": "visit.unscheduled == true if blood_sampling.repeat == true",
        "appliesToActivityIds": [
          "Blood sampling"
        ],
        "sourceText": "e. Unscheduled visits may be necessary during the study to repeat any blood sampling if required."
      },
      {
        "id": "fn_cond_6",
        "conditionType": "timing_after",
        "text": "f. This call or visit will occur 14 (+7) days after the last dose of BIVV001.",
        "footnoteId": "fn_6",
        "structuredCondition": "visit.timing == last_dose + P14D (+ P7D)",
        "appliesToActivityIds": [
          "Follow-up call",
          "Follow-up visit"
        ],
        "sourceText": "f. This call or visit will occur 14 (+7) days after the last dose of BIVV001."
      },
      {
        "id": "fn_cond_7",
        "conditionType": "timing_before",
        "text": "g. Informed consent from the participant or the participant's legal guardian MUST be obtained prior to any study-related procedures.",
        "footnoteId": "fn_7",
        "structuredCondition": "informed_consent.date < procedure.date",
        "appliesToActivityIds": [
          "All study-related procedures"
        ],
        "sourceText": "g. Informed consent from the participant or the participant's legal guardian MUST be obtained prior "
      }
    ],
    "endpointAlgorithms": [
      {
        "id": "ep_1",
        "name": "Key Secondary: Intra-patient comparison of ABR",
        "endpointType": "Secondary",
        "inputs": [
          "ABR_BIVV001_period",
          "ABR_historical_prophylaxis",
          "study_duration_current",
          "study_duration_observational"
        ],
        "timeWindow": {
          "reference": "BIVV001 weekly prophylaxis treatment period",
          "duration": "P6M"
        },
        "algorithm": "ABR_BIVV001_period - ABR_historical_prophylaxis",
        "successCriteria": "Participants in Arm A must have at least 6 months of study duration in both this study and in observational study 242HA201/OBS16221",
        "sourceText": "an intra-patient comparison of ABR during the BIVV001 weekly prophylaxis treatment period versus the historical prophylaxis ABR... participants in Arm A must have at least 6 months of study duration i"
      },
      {
        "id": "ep_2",
        "name": "Patient Reported Outcome: TSQM-9",
        "endpointType": "Secondary",
        "inputs": [
          "TSQM-9_scores"
        ],
        "timeWindow": {
          "reference": "Baseline and specified follow-up visits",
          "duration": "Study duration"
        },
        "algorithm": "Calculation of 9-item Treatment Satisfaction Questionnaire for Medication scores",
        "successCriteria": "Evaluation of treatment satisfaction based on TSQM-9 instrument",
        "sourceText": "the 9-item version of the Treatment Satisfaction Questionnaire for Medication (TSQM-9) is being used"
      },
      {
        "id": "ep_3",
        "name": "Exploratory: Patient expectations and perception",
        "endpointType": "Exploratory",
        "inputs": [
          "Exit_interview_data"
        ],
        "timeWindow": {
          "reference": "Study exit",
          "duration": "Post-treatment"
        },
        "algorithm": "Qualitative/Quantitative analysis of exit interview responses",
        "successCriteria": "Evaluation of participants’ expectations of treatment and perception of treatment impact",
        "sourceText": "An exit interview... related endpoint was added to the exploratory objective for patient reported outcome measures... To evaluate participants’ expectations of treatment and perception of treatment im"
      }
    ],
    "derivedVariables": [
      {
        "id": "dv_1",
        "name": "Patient Global Impression of Change",
        "variableType": "ChangeFromBaseline",
        "sourceVariables": [
          "Patient Global Impression of Severity"
        ],
        "derivationRule": "Assessment of change in status relative to baseline as reported by the participant at specified follow-up visits",
        "baselineDefinition": "Baseline assessment of severity (activity and joint) recorded at Day 1",
        "baselineVisit": "Day 1",
        "analysisWindow": "Week 26 ± 7 days, Week 52 ± 7 days",
        "imputationRule": "Not specified in text",
        "unit": "Scale"
      },
      {
        "id": "dv_2",
        "name": "FVIII Activity Half-life (t1/2)",
        "variableType": "Custom",
        "sourceVariables": [
          "FVIII activity",
          "Time"
        ],
        "derivationRule": "Geometric mean of half-life based on one-stage aPTT clotting assay following IV dose",
        "baselineDefinition": "Predose PK sample",
        "baselineVisit": "Day 1",
        "analysisWindow": "Up to 14 days post-dose",
        "imputationRule": "Not specified in text",
        "unit": "Hours"
      },
      {
        "id": "dv_3",
        "name": "Treatment Emergent Adverse Events (TEAE)",
        "variableType": "Categorical",
        "sourceVariables": [
          "Adverse Event Start Date",
          "Dose Date"
        ],
        "derivationRule": "Events occurring after the first dose of BIVV001 or Advate through the end of the treatment period",
        "baselineDefinition": "First dose of study medication",
        "baselineVisit": "Day 1",
        "analysisWindow": "Treatment period duration",
        "imputationRule": "Not specified in text",
        "unit": "Count"
      },
      {
        "id": "dv_4",
        "name": "FVIII Activity Level at Specific Timepoints",
        "variableType": "Custom",
        "sourceVariables": [
          "FVIII activity",
          "Time"
        ],
        "derivationRule": "Average FVIII activity level as measured by one-stage aPTT assay at 72 hours, 5 days, 7 days, 10 days, or 14 days post-dose",
        "baselineDefinition": "Predose PK sample",
        "baselineVisit": "Day 1",
        "analysisWindow": "72 hours to 14 days post-dose",
        "imputationRule": "Not specified in text",
        "unit": "%"
      }
    ],
    "stateMachine": {
      "id": "sm_1",
      "initialState": "Screening",
      "terminalStates": [
        "Early Termination",
        "Completed"
      ],
      "states": [
        "Screening",
        "Baseline",
        "Treatment Period",
        "End Of Study",
        "Early Termination"
      ],
      "transitions": [
        {
          "fromState": "Screening",
          "toState": "Baseline",
          "trigger": "Progress to Baseline"
        },
        {
          "fromState": "Baseline",
          "toState": "Treatment Period",
          "trigger": "Progress to Treatment Period"
        },
        {
          "fromState": "Treatment Period",
          "toState": "End Of Study",
          "trigger": "Progress to End Of Study"
        },
        {
          "fromState": "Treatment Period",
          "toState": "Early Termination",
          "trigger": "Subject exits to Early Termination"
        }
      ],
      "epochIds": {
        "Screening": "SCREENING",
        "Baseline": "BASELINE",
        "Treatment Period": "TREATMENT_PERIOD",
        "End Of Study": "END_OF_STUDY",
        "Early Termination": "EARLY_TERMINATION"
      }
    },
    "dosingRegimens": [
      {
        "id": "dosing_1",
        "treatmentName": "Following BIVV001",
        "frequency": "QW",
        "route": "Oral",
        "startDay": 1,
        "doseLevels": [
          {
            "amount": 50.0,
            "unit": "iu"
          }
        ],
        "sourceText": "with QW dosing, mean FVIII activities based on one-stage and chromogenic assays were 46.28% and 30.46% at 72 hours, 22.30% and 14.48% at 120 hours, and 9.83% and 6.74% at 168 hours, respectively. Foll"
      },
      {
        "id": "dosing_llm_1",
        "treatmentName": "BIVV001 (efanesoctocog alfa)",
        "frequency": "QW",
        "route": "IV",
        "startDay": 1,
        "durationDescription": "At least 6 months",
        "doseModifications": [
          "Major surgery only allowed after 6 exposure days (EDs)",
          "Negative inhibitor test required within 4 weeks prior to surgery"
        ]
      }
    ],
    "visitWindows": [
      {
        "id": "visit_3",
        "visitName": "Screening",
        "targetDay": -14,
        "windowBefore": 7,
        "windowAfter": 0,
        "isRequired": true,
        "visitNumber": 1,
        "epoch": "Screening",
        "sourceText": "electronic patient diary (ePD) is performed at the Screening visit. ePD devices are given to the patients at the baseline visit. In Section 8.3.8, the following text was added: (if a bleed occurs"
      },
      {
        "id": "visit_1",
        "visitName": "Early Termination",
        "targetDay": null,
        "windowBefore": 0,
        "windowAfter": 0,
        "isRequired": true,
        "visitNumber": 2,
        "sourceText": "Determination The selection of participants to be included in the analysis for the key secondary efficacy endpoint (ie, an intra-patient comparison of"
      },
      {
        "id": "visit_2",
        "visitName": "Visit 001",
        "targetDay": null,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 3,
        "sourceText": "ABR during the BIVV001 weekly prophylaxis treatment period versus the historical prophylaxis ABR) was updated to clarify that participants in Arm A must have at least 6 months of study duration"
      },
      {
        "id": "visit_4",
        "visitName": "baseline",
        "targetDay": 0,
        "windowBefore": 1,
        "windowAfter": 1,
        "isRequired": true,
        "visitNumber": 4,
        "epoch": "Treatment",
        "sourceText": "ePD devices are given to the patients at the baseline visit. In Section 8.3.8, the following text was added: (if a bleed occurs during the Screening period, before the baseline visit, it will be"
      },
      {
        "id": "visit_13",
        "visitName": "EOS",
        "targetDay": null,
        "windowBefore": 7,
        "windowAfter": 7,
        "isRequired": false,
        "visitNumber": 5,
        "sourceText": "EOS/ETc ±7 days Unscheduled"
      },
      {
        "id": "visit_21",
        "visitName": "Visit 52",
        "targetDay": null,
        "windowBefore": 7,
        "windowAfter": 7,
        "isRequired": true,
        "visitNumber": 6,
        "sourceText": "(EOS) Visit 52 weeks (±7 days) post-Baseline, or earlier if EOS has been declared. 4.2 SCIENTIFIC RATIONALE FOR STUDY DESIGN"
      },
      {
        "id": "visit_llm_4",
        "visitName": "Minor Dental Surgery",
        "targetDay": null,
        "windowBefore": 3,
        "windowAfter": 0,
        "isRequired": false,
        "visitNumber": 4,
        "epoch": "Surgical"
      },
      {
        "id": "visit_llm_5",
        "visitName": "Major Surgery",
        "targetDay": null,
        "windowBefore": null,
        "windowAfter": null,
        "isRequired": false,
        "visitNumber": 5,
        "epoch": "Surgical"
      },
      {
        "id": "visit_llm_6",
        "visitName": "Safety Follow-up",
        "targetDay": null,
        "windowBefore": null,
        "windowAfter": null,
        "isRequired": true,
        "visitNumber": 6,
        "epoch": "Follow-up"
      },
      {
        "id": "visit_llm_7",
        "visitName": "Exit Interview",
        "targetDay": null,
        "windowBefore": null,
        "windowAfter": null,
        "isRequired": true,
        "visitNumber": 7,
        "epoch": "End of Study"
      },
      {
        "id": "visit_6",
        "visitName": "Week 1",
        "targetDay": 1,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 11,
        "targetWeek": 1,
        "sourceText": "Table 3 - PK sampling schedule of activities first dose (Week 1) and Week 26 for sequential PK subgroup ................................................................................................"
      },
      {
        "id": "visit_14",
        "visitName": "Day 2",
        "targetDay": 2,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 12,
        "sourceText": "Day 2 Day 4 Day 8d (study drug can be"
      },
      {
        "id": "visit_15",
        "visitName": "Day 4",
        "targetDay": 4,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 13,
        "sourceText": "Day 4 Day 8d (study drug can be taken after assessments on"
      },
      {
        "id": "visit_19",
        "visitName": "Week 2",
        "targetDay": 8,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 14,
        "targetWeek": 2,
        "sourceText": "Note: Participants in the sequential PK subgroup will not receive BIVV001 at Week 2 and Week 27 (or 1 week after the repeat PK). a"
      },
      {
        "id": "visit_17",
        "visitName": "Day 11",
        "targetDay": 11,
        "windowBefore": 0,
        "windowAfter": 0,
        "isRequired": true,
        "visitNumber": 15,
        "sourceText": "Day 11 Day 15e 15 m"
      },
      {
        "id": "visit_18",
        "visitName": "Day 15",
        "targetDay": 15,
        "windowBefore": 0,
        "windowAfter": 0,
        "isRequired": true,
        "visitNumber": 16,
        "sourceText": "Day 15e 15 m (±3 m)"
      },
      {
        "id": "visit_10",
        "visitName": "Week 4",
        "targetDay": 22,
        "windowBefore": 7,
        "windowAfter": 7,
        "isRequired": true,
        "visitNumber": 17,
        "targetWeek": 4,
        "sourceText": "Week 4c ±7 days Week 13c"
      },
      {
        "id": "visit_11",
        "visitName": "Week 13",
        "targetDay": 85,
        "windowBefore": 7,
        "windowAfter": 7,
        "isRequired": true,
        "visitNumber": 18,
        "targetWeek": 13,
        "sourceText": "Week 13c ±7 days Week"
      },
      {
        "id": "visit_7",
        "visitName": "Week 26",
        "targetDay": 176,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 19,
        "targetWeek": 26,
        "epoch": "Treatment",
        "sourceText": "undergo more extensive PK sampling at Baseline and again at Week 26. Participants from any arm who undergo major surgery during the study will be included in the surgery subset. A minimum of 10 major "
      },
      {
        "id": "visit_12",
        "visitName": "Week 39",
        "targetDay": 267,
        "windowBefore": 7,
        "windowAfter": 7,
        "isRequired": true,
        "visitNumber": 20,
        "targetWeek": 39,
        "sourceText": "Week 39c ±7 days Week 52/"
      },
      {
        "id": "visit_8",
        "visitName": "Week 52",
        "targetDay": 358,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 21,
        "targetWeek": 52,
        "sourceText": "3 endpoints from baseline to Week 52, along with its 95% CI, will be estimated by the MMRM model. Analysis of other secondary efficacy endpoints: All secondary efficacy endpoints will be"
      },
      {
        "id": "visit_5",
        "visitName": "Follow-up",
        "targetDay": 365,
        "windowBefore": 7,
        "windowAfter": 7,
        "isRequired": true,
        "visitNumber": 22,
        "sourceText": "Table 1 - Overall schedule of activities from screening to safety follow-up call or visit................................. 17 Table 2 - Abbreviated PK sampling schedule of activities ................."
      }
    ],
    "randomizationScheme": {
      "id": "randomization_1",
      "ratio": "357:535",
      "method": "Simple randomization",
      "centralRandomization": true,
      "sourceText": "Amended clinical Trial Protocol 05 \nEFC16293 - efanesoctocog alfa       \n20-Aug-2021 \nVersion number: 1 \n \nProperty of the Sanofi group - strictly confidential \nPage 27 \nhemophilia A is estimated to b"
    }
  }
}